Aster Insights was founded in 2006 on the unique principle that informed consent from patients entrusting us with a lifetime connection to their health information, paired with deep partnerships across academia and the life sciences industry, will unlock critical advances in curing cancer.
We lead the Oncology Research Information Exchange Network (ORIEN®), a unique research partnership among top national academic cancer centers that recognize collaboration and access to quality data are the keys to cancer discovery.
ORIEN® member institutions conduct Total Cancer Care®, the world's largest and longest-running observational research study in oncology, which has enrolled nearly half a million patients representing all types of cancer. Through TCC®, patients provide lifetime consent to their health information and donate tissue for molecular analysis to advance research and cures for cancer.
Because patients participating in TCC® provide lifetime consent, we are able to learn from their experiences, and provide insights into potential new treatments throughout their journey. Consented patients agree to be contacted for future studies and have an active role in the study of their cancer, treatment options, and the larger impact of improving care for future generations.
Using the information learned from patients through TCC® and ORIEN®, Aster Insights partners with drug, biologics, diagnostics and medical device developers to accelerate discovery and development of oncology medical products. We deliver solutions that empower our partners to enhance cancer detection, deepen our understanding of new treatments, accelerate clinical trials, and improve outcomes for patients with cancer. Together, we are changing the way cancer is studied, treated, and prevented.